Which way forward for treatment of severe ocular inflammation?

Clin Exp Ophthalmol. 2006 May-Jun;34(4):293-4. doi: 10.1111/j.1442-9071.2006.01244.x.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Anti-Inflammatory Agents / economics
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal / therapeutic use
  • Drug Costs
  • Glucocorticoids / economics
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / economics
  • Immunosuppressive Agents / therapeutic use*
  • Inflammation / drug therapy
  • Inflammation / economics
  • Infliximab
  • Interferon-alpha / economics
  • Interferon-alpha / therapeutic use
  • Triamcinolone Acetonide / economics
  • Triamcinolone Acetonide / therapeutic use
  • Uveitis / drug therapy*
  • Uveitis / economics

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Glucocorticoids
  • Immunosuppressive Agents
  • Interferon-alpha
  • Infliximab
  • Triamcinolone Acetonide